Form 4: CFO Deina Walsh Acquires Bone Biologics Stock Options
Insider Transaction Report
Bone Biologics Corp's CFO, Deina Walsh, was granted 8,335 employee stock options with an exercise price of $1.55, effective January 8, 2026.
Summary
- Deina H. Walsh, Chief Financial Officer of Bone Biologics Corp (BBLG), reported changes in beneficial ownership.
- Walsh acquired 8,335 employee stock options on January 8, 2026, with an exercise price of $1.55 per share.
- These newly granted options were issued under the Bone Biologics Corporation 2015 Equity Incentive Plan and vest immediately.
- The newly acquired options have an expiration date of January 8, 2036.
- Walsh also beneficially owns 4,510 fully vested employee stock options with an exercise price of $5.82, which expire on January 15, 2027.
- Walsh directly owns 313 shares of Bone Biologics Corp Common Stock.
Sentiment
Score: 7
Explanation: The grant of stock options to a key executive like the CFO is generally a positive signal, indicating alignment of interests and potential confidence in future growth. The immediate vesting is also a positive sign. However, it's a routine transaction and does not provide deep insight into company performance or financial health.
Positives
- CFO Deina Walsh received a significant grant of 8,335 employee stock options, which aligns her interests with those of shareholders.
- The newly granted options vest and become exercisable immediately, providing immediate equity exposure.
- The exercise price of $1.55 for the new options is relatively low, suggesting potential upside if the company's stock price increases.
Risks
- The value of the stock options is contingent on the future performance of Bone Biologics Corp's common stock.
- If the stock price does not exceed the respective exercise prices of $1.55 and $5.82, the options may expire worthless.
Future Outlook
This filing is an insider transaction report and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
The grant of stock options to key executives is a common compensation practice across various industries, including the biotechnology and medical device sectors where Bone Biologics Corp operates. This practice aims to incentivize management and align their financial interests with long-term shareholder value creation.
Stakeholder Impact
- Shareholders: The grant of stock options to the Chief Financial Officer aligns her incentives with the goal of increasing shareholder value, as the options' value is tied to the company's stock performance.
Key Dates
| Date | Description |
|---|---|
| 01/08/2026 | Date of earliest transaction: Grant of 8,335 employee stock options. |
| 01/15/2027 | Expiration date of 4,510 employee stock options with an exercise price of $5.82. |
| 01/08/2036 | Expiration date of 8,335 employee stock options with an exercise price of $1.55. |
| 01/20/2026 | Signature date of the reporting person on the Form 4. |
Keywords
Bone Biologics Corp, BBLG, SEC Form 4, Stock Options, Employee Stock Option, CFO, Deina Walsh, Equity Incentive Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.